Business Wire

Morgan Stanley Expands Global Inclusive Ventures Lab with Largest Single Cohort of 23 Companies

12.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Morgan Stanley (NYSE: MS) today announced the 2023 global cohort of the Inclusive Ventures Lab, with 23 companies selected across North America and Europe, the Middle East and Africa (EMEA), double the size of previous cohorts. The Lab offers a five-month in-house accelerator program for underrepresented founders of technology and technology-enabled startups in the post-seed to Series A funding round stage.

Chosen from over 7,900 applicants – more than three times last year’s pool – the selected startups represent a range of disruptive technologies in industries including healthcare, sustainable solutions, customer service, supply chain, recruiting and cybersecurity. Companies in the cohort receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners.

“We are proud to welcome the Lab’s largest cohort yet, marking our continued efforts to create a more equitable investment landscape for overlooked entrepreneurs worldwide,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “We are working to bridge the investment gap for underserved founders and to help correct documented market imbalances.”

The selected companies in the 2023 global cohort include the following:

  • Ad Auris empowers marketing teams, publishers and content creators to repurpose written content into high-quality audio to reach an audience of listeners (Canada)
  • Automated Architecture provides the technological infrastructure for a distributed robotic micro-factory network producing sustainable timber housing (UK)
  • Bidrento offers an all-in-one solution for tenant experience and rental property management, helping to save time and money while also reducing CO2 emissions in real estate (Estonia)
  • ByFusion provides a zero waste landfill diversion platform to transform non-recyclable plastic waste into reusable building materials (US)
  • Cult Mia is an online fashion marketplace for sustainable and ethical brands from around the world (UK)
  • DotLab develops breakthrough, actionable AI and ML technologies that lead to better health outcomes for women, starting with the diagnosis of endometriosis (US)
  • eBanqo offers businesses an omnichannel platform to drive customer engagement and support (Nigeria)
  • Encounter AI uses digital conversational ordering solutions to provide faster, friendlier and more efficient service to customers, restaurants and retailers (US)
  • FLUIX Inc. enterprise AI software saves critical infrastructure on energy costs by integrating and optimizing facility systems (US)
  • GigBridge is an online platform for construction companies to hire, onboard and pay their workforce all in one place (UK)
  • Health in Her HUE connects Black women and women of color to culturally sensitive healthcare providers, health content and community support through a digital platform (US)
  • Inicio AI delivers a virtually guided affordability assessment to help organizations save contact center costs while improving their end customer experience (UK)
  • MEDIjobs is the first virtual recruiter for the healthcare industry, filling more than 55 types of positions at a rate five times faster than a human would (US)
  • Nopalera is a collection of bath and body products powered by Mexico’s nopal cactus – an ancient symbol of Mexican culture (US)
  • OKO offers affordable and inclusive crop insurance to farmers in emerging countries using satellite weather data and mobile payment technologies (Israel)
  • Oppos provides robust cybersecurity and compliance security solutions for businesses, safeguarding data confidentiality, integrity, and availability (Canada)
  • Partsimony enables organizations to build intelligent manufacturing supply chains that are more resilient and sustainable by unifying engineering and supply chain data (US)
  • Ridelink leverages technology to enable small and medium-sized businesses to move cargo in Uganda and cross-border in six neighboring countries (Uganda)
  • serviceMob is an AI & ML-powered customer service analytics platform that helps businesses optimize operations and improve the customer experience (US)
  • Stak Mobility facilitates widespread urban electric vehicle adoption by merging space-saving vertical parking automation with fully integrated EV charging and a seamless mobile self-service experience (US)
  • Tall Poppy is a digital security company protecting employees and public facing teams from online threats (US)
  • Twipes uses bio-tech to produce flushable, biodegradable wet wipes that break down in water in three hours and biodegrade in landfills in seven days (US)
  • Unfabled is a consumer health platform that delivers personalized solutions for women by matching them with health and wellness products (UK)

“We are thrilled to bring our unique accelerator program to more entrepreneurs globally, including our first participants from Africa and the Middle East,” said Sanghamitra Karra, EMEA Head of the Inclusive Ventures Group. “It is highly rewarding to work closely with founders to take their game-changing technologies to scale and help set them up for continued success.”

“By providing these promising startups with much-needed capital, a tailored curriculum and access to investors within and beyond the Firm’s far-reaching network, we aim to ensure that more underrepresented founders can succeed,” said LaToya Wilson, Americas Head of the Inclusive Ventures Group.

Programming will run through February 2024 and culminate in a global Demo Day, when participating companies will present to potential investors, business partners and customers.

The Inclusive Ventures Lab has won multiple Gold Anthem Awards, including Most Impactful Corporate Initiative in 2022 and Corporate Social Responsibility in 2023. The program was also listed as one of Global Finance’s Best Innovation Labs of 2023.

About the Morgan Stanley Inclusive Ventures Lab

The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of underrepresented founders, which our research shows equals over four trillion dollars in unrealized returns.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations: Carrie Hall, carrie.hall@morganstanley.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye